RASP (Actavia Life Sciences) YoY EBITDA Growth: 100.00% (As of Mar. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Actavia Life Sciences YoY EBITDA Growth?

Actavia Life Sciences RASP -87.50% YoY EBITDA Growth is 100.00% as of Mar. 2024.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Actavia Life Sciences's YoY EBITDA Growth for the quarter that ended in Mar. 2024 was 100.00%.

Actavia Life Sciences's EBITDA per Share for the three months ended in Mar. 2024 was $0.00.

Actavia Life Sciences YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Actavia Life Sciences's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Actavia Life Sciences YoY EBITDA Growth Chart

Actavia Life Sciences Annual Data
Trend Jun14 Jun15 Jun16 Mar17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 77.97 -492.31 93.51 140.00 -450.00

Actavia Life Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -450.00 0.00 0.00 100.00 100.00

Actavia Life Sciences YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Actavia Life Sciences's YoY EBITDA Growth for the fiscal year that ended in Sep. 2023 is calculated as:

YoY EBITDA Growth (A: Sep. 2023 )
=(EBITDA per Share (A: Sep. 2023 )-EBITDA per Share (A: Sep. 2022 ))/ | EBITDA per Share (A: Sep. 2022 ) |
=(-0.007-0.002)/ | 0.002 |
=-450.00 %

Actavia Life Sciences's YoY EBITDA Growth for the quarter that ended in Mar. 2024 is calculated as:

YoY EBITDA Growth (Q: Mar. 2024 )
=(EBITDA per Share (Q: Mar. 2024 )-EBITDA per Share (Q: Mar. 2023 )) / | EBITDA per Share (Q: Mar. 2023 )) |
=(-0--0.007)/ | -0.007 |
=100.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 100.00% mean?
Actavia Life Sciences (RASP) has a YoY EBITDA Growth of 100.00% as of Mar. 2024. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Actavia Life Sciences and its competitors.
Is Actavia Life Sciences' YoY EBITDA Growth too high?
Actavia Life Sciences' current YoY EBITDA Growth is 100.00%.
How does Actavia Life Sciences' YoY EBITDA Growth compare to BWV and FNCH?
Actavia Life Sciences' YoY EBITDA Growth of 100.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Actavia Life Sciences and its competitors. Actavia Life Sciences's current YoY EBITDA Growth is 100.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actavia Life Sciences stock overvalued right now?
Actavia Life Sciences (RASP) has a current YoY EBITDA Growth of 100.00%. The current YoY EBITDA Growth is 100.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Actavia Life Sciences (RASP), the current YoY EBITDA Growth is 100.00% as of Mar. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Actavia Life Sciences Business Description

Address 5 Penn Plaza, No.1954, 19th Floor, New York, NY, USA, 10001
Actavia Life Sciences Inc is a clinical-stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, mainly focusing on the treatment of leukemia. Its primary indication is Acute Myeloid Leukemia (AML), which may be fatal within weeks to months, has about a 5-year survival rate of only about 25% and very poor prospects for the long-term survival of patients.